Regulation: when less is more
Slides from Clive Bates' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
En el siguiente documento podrá conocer el tamaño de mercado, las condiciones de acceso por producto, los canales de comercialización y las oportunidades de exportación para algunos productos priorizados en Alemania.
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosLindsay Fox
Research on Safety of Electronic Cigarettes
Slides from Dr. Konstantinos Farsalinos' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Professor Robert WestLindsay Fox
Trends in electronic cigarette use in England
Slides from Prof Robert West's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
En el siguiente documento podrá conocer el tamaño de mercado, las condiciones de acceso por producto, los canales de comercialización y las oportunidades de exportación para algunos productos priorizados en Alemania.
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Research on Safety of Electronic Cigarettes - Dr. Konstantinos FarsalinosLindsay Fox
Research on Safety of Electronic Cigarettes
Slides from Dr. Konstantinos Farsalinos' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Professor Robert WestLindsay Fox
Trends in electronic cigarette use in England
Slides from Prof Robert West's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Electronic Cigarette Regulations: When Less is Moreecigarettesummit
Clive Bates, speaker at E-Cigarette Summit London, discusses regulations surrounding electronic cigarettes. He points out that tight regulations could harm the e-cig industry and push people back to smoking tobacco. Visit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
The APPH Standard: What Does it Actually Mean?Clive Bates
My presentation at the Food & Drug Law Institute Tobacco and Nicotine conference 26 October 2023. I discuss five problems with the APPH concept:
1. No means of trading off different types of benefits and detriments
2. Ignores vaping benefits to youth
3. Blind to harmful unintended consequences of marketing denial orders
4. Impossible to estimate population effects at the product level - the standard only makes sense at the category level.
5. The aggregate effect of thousands of single product PMTA determinations may create adverse effects not captured in any individual application (de fact flavour ban)
I finish with three broad proposals:
1. Assess individual risk and marketing strategy pre-market
2. Assess population effects when it is actually possible to observe them - post-market
3. Conduct a single comprehensive market assessment covering all products, including illicit trade
Presentation by Anca Toma Friedlaender (Senior Policy Advisor, Smoke Free Partnership) on the occasion of the EESC hearing on Manufacture, presentation and sale of tobacco and related products (Brussels, 19 Feb 2013).
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...Lindsay Fox
How E-Cigarettes Should be Regulated
Slides from Jean-François ETTER's presentation at the E-Cigarette Summit, London November 12, 2013.
Summary of evidence:
1. E-cigarettes are used by current and former smokers, as a cheaper and safer alternative to tobacco
2. Most users report that e-cigs help them quit or reduce smoking
3. Regular or daily use in non-smokers has not been documented so far
4. E-cigs are less addictive and less toxic than cigarettes
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
US E-cigarette Summit: Taming the nicotine industrial complexClive Bates
I look back to 1997 and simpler time in tobacco control, then look at changes in trade, communications, technology and conclude the market is becoming ungovernable
The end of what? UK E-cigarette Summit 2023Clive Bates
The extended version of my presentation to the UK E-cigarette summit 16 November 2023. We look at the following:
1. End of harm or end of nicotine
2. The demand for nicotine
3. The future market for nicotine
4. False risk perceptions
5. Who is to blame
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Electronic Cigarette Regulations: When Less is Moreecigarettesummit
Clive Bates, speaker at E-Cigarette Summit London, discusses regulations surrounding electronic cigarettes. He points out that tight regulations could harm the e-cig industry and push people back to smoking tobacco. Visit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
The APPH Standard: What Does it Actually Mean?Clive Bates
My presentation at the Food & Drug Law Institute Tobacco and Nicotine conference 26 October 2023. I discuss five problems with the APPH concept:
1. No means of trading off different types of benefits and detriments
2. Ignores vaping benefits to youth
3. Blind to harmful unintended consequences of marketing denial orders
4. Impossible to estimate population effects at the product level - the standard only makes sense at the category level.
5. The aggregate effect of thousands of single product PMTA determinations may create adverse effects not captured in any individual application (de fact flavour ban)
I finish with three broad proposals:
1. Assess individual risk and marketing strategy pre-market
2. Assess population effects when it is actually possible to observe them - post-market
3. Conduct a single comprehensive market assessment covering all products, including illicit trade
Presentation by Anca Toma Friedlaender (Senior Policy Advisor, Smoke Free Partnership) on the occasion of the EESC hearing on Manufacture, presentation and sale of tobacco and related products (Brussels, 19 Feb 2013).
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...Lindsay Fox
How E-Cigarettes Should be Regulated
Slides from Jean-François ETTER's presentation at the E-Cigarette Summit, London November 12, 2013.
Summary of evidence:
1. E-cigarettes are used by current and former smokers, as a cheaper and safer alternative to tobacco
2. Most users report that e-cigs help them quit or reduce smoking
3. Regular or daily use in non-smokers has not been documented so far
4. E-cigs are less addictive and less toxic than cigarettes
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
US E-cigarette Summit: Taming the nicotine industrial complexClive Bates
I look back to 1997 and simpler time in tobacco control, then look at changes in trade, communications, technology and conclude the market is becoming ungovernable
The end of what? UK E-cigarette Summit 2023Clive Bates
The extended version of my presentation to the UK E-cigarette summit 16 November 2023. We look at the following:
1. End of harm or end of nicotine
2. The demand for nicotine
3. The future market for nicotine
4. False risk perceptions
5. Who is to blame
Similar to E-Cigarette Summit Speaker: Clive Bates (20)
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
4. I smoked for 45 years and tried every NRT
product available, none of them worked. I
continued to smoke even though my health was
getting worse, resulting in COPD and using
oxygen daily.
September 2011 I discovered e-cigarettes and
they worked. It was like someone handed me a
miracle. In less than a week I stopped using
regular cigarettes. I haven’t had a tobacco
cigarette since.
Unsolicited comment left on www.clivebates.com
6. The Endgame?
Billion adults > 15 years
Projected global adult population growth
9.0
8.0
Adult
population
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
2010
2015
2020
2025
2030
2035
Smokers: WHO Tobacco Atlas 2006. Population: UN
2040
2045
2050
7. The Endgame?
Billion adults > 15 years
Projected global adult population growth
9.0
8.0
Adult
population
7.0
6.0
5.0
4.0
3.0
Smoker
population at
constant
prevalence
2.0
1.0
0.0
2010
2015
2020
2025
2030
2035
Smokers: WHO Tobacco Atlas 2006. Population: UN
2040
2045
2050
8. The endgame?
Billion adults > 15 years
Scenarios for future smoker population
2.5
Constant
prevalence
(28%)
2.0
1.5
1.0
0.5
0.0
2010
2015
2020
2025
2030
Scenario – 15% global prevalence by 2050
2035
2040
2045
2050
9. The endgame?
Billion adults > 15 years
Scenarios for future smoker population
2.5
Constant
prevalence
(28%)
2.0
1.5
Global smoking
prevalence
declines to 15%
1.0
0.5
0.0
2010
2015
2020
2025
2030
Scenario – 15% global prevalence by 2050
2035
2040
2045
2050
10. If all goes well
Billion adults > 15 years
Scenarios for future smoker population
2.5
Constant
prevalence
(28%)
2.0
Contested by tobacco control
1.5
Global smoking
prevalence
declines to 15%
1.0
HARM
0.5
0.0
2010
2015
2020
2025
2030
2035
2040
2045
2050
11. The endgame – a nicotine product contest?
Billion adults > 15 years
Scenarios for future nicotine markets
2.5
Constant
prevalence
(28%)
2.0
Contested by tobacco control
1.5
Global nicotine
prevalence
declines to 15%
1.0
Contested by nicotine products
0.5
0.0
2010
2015
2020
2025
2030
2035
2040
2045
2050
12. How far could low-risk nicotine products go?
Billion adults > 15 years
Scenarios for future nicotine markets
2.5
Constant
prevalence
(28%)
2.0
Contested by tobacco control
1.5
Global nicotine
prevalence
declines to 15%
1.0
Contested by low risk nicotine products
Global smoking
prevalence
declines to 5%
0.5
Cigarettes and other combustible tobacco
0.0
2010
2015
2020
2025
2030
2035
2040
2045
2050
13. How far could low-risk nicotine products go?
Billion adults > 15 years
Scenarios for future nicotine markets
2.5
2.0
1.5
1.0
This boundary matters most for public health
0.5
0.0
2010
2015
2020
2025
2030
2035
2040
2045
2050
14. The endgame: analyst view
Consumption of e-cigs may overtake traditional
cigarettes in the next decade … and they’ll only
evolve and improve as time goes forward.
Bonnie Herzog, Wells Fargo Securities, 2013
15. The endgame: analyst view
Consumption of e-cigs may overtake traditional
cigarettes in the next decade … and they’ll only
evolve and improve as time goes forward.
Bonnie Herzog, Wells Fargo Securities, 2013
16. 50:50 by 2030
Billion adults > 15 years
”Modified Herzog scenario" for future nicotine markets
2.5
Constant
prevalence
(28%)
2.0
1.5
Global nicotine
prevalence
declines to 15%
1.0
"E-cigarettes overtake
cigarettes by 2030"
0.5
0.0
2010
Global smoking
prevalence
declines to 5%
2015
2020
2025
2030
2035
2040
2045
2050
17. Who is this?
Mitch Zeller
(now) Director of the Center for Tobacco Products
FDA
18. Harm reduction equation
Harm reduction = Reduced risk x Number who switch
Product toxicity &
other risks
Product attractiveness
Consumer preference
19. Harm reduction equation
Harm reduction = Reduced risk x Number who switch
Product toxicity &
other risks
Product attractiveness
Consumer preference
21. Focus on the right relative risk
More regulation
Lower risk
regulated e-cig
0
10
0
e-cigarettes
“unregulated” e-cig
10
0
100
cigarette
22. Harm reduction equation
Harm reduction = Reduced risk x Number who switch
Product toxicity &
other risks
Product attractiveness
Consumer preference
23. Analysts
We remain very bullish on the vast potential of e-cigs given the
rapid pace of innovation. [We believe] that the benefits of e-cigs
are becoming increasingly apparent to consumers, helping to
drive trial and repeat purchases aided by stepped-up advertising
and a lot of internet “buzz”
Wells Fargo
24. Regulation comes at a price
Fewer, duller
innovations
Less
personalisation
Slower
innovation
pace
Trusted brands
& firms
destroyed
Greatly
reduced variety
& niche
products
Increased cost
Boring
branding &
marketing
Oligopoly &
reduced
competition
Reduced
appeal
Black market,
DIY
25. Harm reduction equation
Harm reduction = Reduced risk x Number who switch
Trade offs
Conclusion 1. The perfectly risk free product that no-one
wants scores badly in the harm reduction equation
Conclusion 2. A diverse range of products with substantially
reduced risk lets each smoker decide which product is best
29. Getting tough on harm reduction?
Counter-productive
Harm reducing
Safety
Safest possible
Safe enough
Quality
Control processes (eg. GMP)
Proportionate standards
Efficacy
Regulator decides
Consumer decides
Labelling
Warns of danger
Encourages switching
Marketing
Like medicines
Like consumer products
Bans on use
Fear of ‘renormalisation’
Normalise harm reduction
Retail
Pharmacies / as tobacco
General sales
Age restrictions
Adults
Makes little real difference
Taxation
Like tobacco
Fiscal incentive to switch
30. What do analysts think…?
We believe many current suppliers would struggle to meet
medical standards, and for the UK they may have to by 2016. Big
players with deeper pockets would survive and prices could rise
– a hugely preferable outcome for Tobacco.
BNP Paribas
Tougher regulation, as well as providing a relative advantage to
their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by
limiting their attraction for smokers and slowing the decline in
tobacco sales.
Fitch
31. What do analysts think…?
We believe many current suppliers would struggle to meet
medical standards, and for the UK they may have to by 2016. Big
players with deeper pockets would survive and prices could rise
– a hugely preferable outcome for Tobacco.
BNP Paribas
Tougher regulation, as well as providing a relative advantage to
their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by
limiting their attraction for smokers and slowing the decline in
tobacco sales.
Fitch
32. European Parliament – amendment 170
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Requires medicines regulation if claim made
Requires Article 17 notification regime otherwise
Emphasises general safety requirement
Applies Article 16 – cross border distance sales
Applies advertising directive 2003/33/EC and audiovisual services 2010/13/EU
Information leaflet
Warning “this product is intended for use by existing smokers. It contains
nicotine which is a highly addictive substance”
Warning size - 30% or 40% (Council =30%) and specification from Article 10
30mg/ml threshold – “are not placed on the market” (?medicine)
Age restriction (no less than 18)
Restriction on additives – application of Article 6.4 (vitamins etc)
No tobacco branding
Allows flavourings
Requires sales allowed ‘outside pharmacies’
Review
33.
34.
35. Purpose built regulation for e-cigs / NCPs
1.
Accountabilities – responsible person
2.
Disclosure and notification regime
3.
Labeling and consumer information
4.
Safety assessment and product file
5.
Contaminants / purity
6.
Prohibited ingredients
7.
Specific standards for vaping devices CEN/ISO
8.
Updating: review & technical committee
9.
Marketing (like alcohol?) – mostly member state
10. Retail sales age restriction – member states
11. … public vaping?
36. Harm reduction equation with population effects
Harm reduction = Reduced risk x Number who switch
- Extra smokers + Extra quitters
Gateway to smoking
Dual use
Reduced quitting
Normalising smoking
Gateway exits
Complete cessation
Extra quitting
Normalising non-smoking
37. Conclusion
• Be positive about the (vast) potential
• Put the (minor) risks in perspective
• Regulate as though the 1 billion matter most